BR112021021350A2 - Entrega intracelular de anticorpos anti kras formulados em nanocápsulas - Google Patents
Entrega intracelular de anticorpos anti kras formulados em nanocápsulasInfo
- Publication number
- BR112021021350A2 BR112021021350A2 BR112021021350A BR112021021350A BR112021021350A2 BR 112021021350 A2 BR112021021350 A2 BR 112021021350A2 BR 112021021350 A BR112021021350 A BR 112021021350A BR 112021021350 A BR112021021350 A BR 112021021350A BR 112021021350 A2 BR112021021350 A2 BR 112021021350A2
- Authority
- BR
- Brazil
- Prior art keywords
- kras
- nanocapsules
- nanoentities
- intracellular delivery
- antibodies formulated
- Prior art date
Links
- 230000003834 intracellular effect Effects 0.000 title abstract 2
- 239000002088 nanocapsule Substances 0.000 title abstract 2
- 101150105104 Kras gene Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
entrega intracelular de anticorpos anti kras formulados em nanocápsulas. trata se de uma composição que compreende: uma pluralidade de nanoentidades que compreendem um núcleo interno rodeado por um invólucro externo, sendo que o invólucro externo compreende um polímero, o núcleo interno compreende pelo menos um composto hidrofóbico, em que as nanoentidades compreendem um agente farmacêutico, em que o agente farmacêutico é um anticorpo ou um fragmento do mesmo, em que o anticorpo ou o fragmento do mesmo se liga a um epítopo de uma proteína kras mutada ativada. esses anticorpos anti kras formulados em nanoentidades particulares que são capazes de ser entregues de modo intracelular e, ainda, são capazes de realizar sua atividade biológica dentro da célula, sendo assim úteis no tratamento de câncer e outras doenças associadas a uma mutação em um gene kras.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19172120 | 2019-05-01 | ||
EP20382206 | 2020-03-19 | ||
PCT/EP2020/062002 WO2020221849A1 (en) | 2019-05-01 | 2020-04-30 | Intracellular delivery of anti-kras antibodies formulated into nanocapsules |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021350A2 true BR112021021350A2 (pt) | 2022-01-18 |
Family
ID=70476239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021350A BR112021021350A2 (pt) | 2019-05-01 | 2020-04-30 | Entrega intracelular de anticorpos anti kras formulados em nanocápsulas |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220177603A1 (pt) |
EP (1) | EP3962491A1 (pt) |
JP (1) | JP2022530613A (pt) |
KR (1) | KR20220004042A (pt) |
CN (1) | CN113825515A (pt) |
AU (1) | AU2020266770A1 (pt) |
BR (1) | BR112021021350A2 (pt) |
CA (1) | CA3137661A1 (pt) |
MX (1) | MX2021013091A (pt) |
WO (1) | WO2020221849A1 (pt) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443956A (en) | 1985-01-29 | 1995-08-22 | Oncogene Science, Inc. | Detection, quantitation and classification of RAS proteins in body fluids and tissues |
US5084380A (en) | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
CA1296660C (en) | 1985-01-29 | 1992-03-03 | Walter P. Carney | Monoclonal antibody against a ras oncogene p21 related dodecapeptide |
US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
KR101602870B1 (ko) * | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
KR101602876B1 (ko) * | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
WO2018069871A2 (en) * | 2016-10-13 | 2018-04-19 | Sorrento Therapeutics, Inc. | Anti-kras binding proteins |
ES2711669A1 (es) | 2017-11-02 | 2019-05-06 | Univ Santiago Compostela | Sistemas de liberacion de farmacos de acido polisialico y metodos |
-
2020
- 2020-04-30 CN CN202080031612.0A patent/CN113825515A/zh active Pending
- 2020-04-30 MX MX2021013091A patent/MX2021013091A/es unknown
- 2020-04-30 US US17/602,061 patent/US20220177603A1/en active Pending
- 2020-04-30 JP JP2021561802A patent/JP2022530613A/ja active Pending
- 2020-04-30 KR KR1020217034617A patent/KR20220004042A/ko unknown
- 2020-04-30 WO PCT/EP2020/062002 patent/WO2020221849A1/en active Search and Examination
- 2020-04-30 CA CA3137661A patent/CA3137661A1/en active Pending
- 2020-04-30 AU AU2020266770A patent/AU2020266770A1/en not_active Abandoned
- 2020-04-30 EP EP20722582.2A patent/EP3962491A1/en active Pending
- 2020-04-30 BR BR112021021350A patent/BR112021021350A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020221849A1 (en) | 2020-11-05 |
JP2022530613A (ja) | 2022-06-30 |
MX2021013091A (es) | 2021-11-17 |
KR20220004042A (ko) | 2022-01-11 |
EP3962491A1 (en) | 2022-03-09 |
CA3137661A1 (en) | 2020-11-05 |
AU2020266770A1 (en) | 2021-10-14 |
US20220177603A1 (en) | 2022-06-09 |
CN113825515A (zh) | 2021-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wood et al. | Ciliary ectosomes: transmissions from the cell's antenna | |
Wang et al. | Autophagy dysfunction, cellular senescence, and abnormal immune‐inflammatory responses in AMD: From mechanisms to therapeutic potential | |
Ono et al. | IL-17-producing γδ T cells enhance bone regeneration | |
Yao et al. | Tumor necrosis factor-α increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression | |
Lee et al. | Stromal response to Hedgehog signaling restrains pancreatic cancer progression | |
Babapoor-Farrokhran et al. | Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy | |
Yuste et al. | The contribution of apoptosis-inducing factor, caspase-activated DNase, and inhibitor of caspase-activated DNase to the nuclear phenotype and DNA degradation during apoptosis | |
Hagen et al. | Omega-1 knockdown in Schistosoma mansoni eggs by lentivirus transduction reduces granuloma size in vivo | |
Satoh et al. | NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
Wang et al. | miR-126 regulation of angiogenesis in age-related macular degeneration in CNV mouse model | |
Lee et al. | KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers | |
Obukuro et al. | Nitric oxide mediates selective degeneration of hypothalamic orexin neurons through dysfunction of protein disulfide isomerase | |
BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
AR028927A1 (es) | Anticuerpo monoclonal humano contra la molecula co-estimuladora ailim transductora de senales y uso farmaceutico del mismo | |
Hoppe et al. | Mast cells initiate the vascular response to contact allergens by sensing cell stress | |
Chaib-Mezrag et al. | Tax impairs DNA replication forks and increases DNA breaks in specific oncogenic genome regions | |
Potter et al. | A strategy to eradicate well-developed Krebs-2 ascites in mice | |
Schiera et al. | Molecular determinants of malignant brain cancers: from intracellular alterations to invasion mediated by extracellular vesicles | |
Shang et al. | Artesunate interacts with the vitamin D receptor to reverse sepsis‐induced immunosuppression in a mouse model via enhancing autophagy | |
Hong et al. | Viral/nonviral chimeric nanoparticles to synergistically suppress leukemia proliferation via simultaneous gene transduction and silencing | |
Wang et al. | A versatile genetic control system in mammalian cells and mice responsive to clinically licensed sodium ferulate | |
Persico et al. | Tackling the behavior of cancer cells: molecular bases for repurposing antipsychotic drugs in the treatment of glioblastoma | |
Munster et al. | Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles | |
Schulz et al. | ABCB1 and ABCG2 regulation at the blood-brain barrier: potential new targets to improve brain drug delivery |